ITM-11 significantly improved progression-free survival over everolimus in GEP-NETs patients, marking a first for targeted radiopharmaceutical therapy in a phase 3 trial. The COMPETE trial included ...
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). Background: CDKs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback